Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Atara Biotherapeutics, Inc. reported revenue of $121M, down 6.3% year over year. Operating margin was 29.7% and net margin 27.1%, on a free-cash-flow margin of -42.2% with capital expenditure at 0.0% of revenue. Every figure is computed directly from ATRA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $121M | 29.7% | 27.1% |
| FY2024 | $129M | -64.7% | -66.2% |
| FY2023 | $9M | -3219.5% | -3220.9% |
| FY2022 | $64M | -441.2% | -359.1% |
| FY2021 | n/a | n/a | n/a |
How does ATRA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.